Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada [Yahoo! Finance]
HIKMA PHARMS PLC S/ADR (HKMPY)
NASDAQ:AMEX Investor Relations:
hikma.com/en/investors.html
Company Research
Source: Yahoo! Finance
Maxigesic® IV approved in Canada Liège, Belgium – 27 February 2024, 06:00 PM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) , a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Hikma Pharmaceuticals (Hikma) has launched Maxigesic® IV in the U.S. under the tradename Combogesic® IV. Stijn Van Rompay, Chief Executive Officer of Hyloris, commented “I am delighted with the rapid marketing launch by our partner Hikma Pharmaceuticals, a leading supplier of injectable medicines globally. The initial feedback from the market is encouraging. Combogesic® IV represents a significant innovation in pain management, offers effective pain relief and importantly provides clinicians a valuable alternative to opioid analgesics.” Hyloris is entitled to a milestone payment of USD 1,1 million, in addition to the USD 1 million that became due upon product manufacturing, which o
Show less
Read more
Impact Snapshot
Event Time:
HKMPY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HKMPY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HKMPY alerts
High impacting HIKMA PHARMS PLC S/ADR news events
Weekly update
A roundup of the hottest topics
HKMPY
News
- With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns [Yahoo! Finance]Yahoo! Finance
- Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform [Yahoo! Finance]Yahoo! Finance
- Merck's Bridion faces generic threat from drugmaker Hikma [Reuters]Reuters
- Merck's Bridion faces generic threat from drugmaker Hikma [Yahoo! Finance]Yahoo! Finance
- Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityPR Newswire